Shopping Cart
- Remove All
- Your shopping cart is currently empty
Grisnilimab setaritox (WT1-RTA), an anti-CD7 antihuman T cell antibody linked to ricin A chain (RTA), exhibits in vitro cytotoxicity against CEM (T-lymphoblastic leukemia) cells with an ID 50 of 53 pM. The 30-kDa RTA component disrupts the function of 60S ribosomal subunits. Additionally, Grisnilimab setaritox has demonstrated efficacy in ameliorating leukemic meningitis in a rhesus monkey model [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Grisnilimab setaritox (WT1-RTA), an anti-CD7 antihuman T cell antibody linked to ricin A chain (RTA), exhibits in vitro cytotoxicity against CEM (T-lymphoblastic leukemia) cells with an ID 50 of 53 pM. The 30-kDa RTA component disrupts the function of 60S ribosomal subunits. Additionally, Grisnilimab setaritox has demonstrated efficacy in ameliorating leukemic meningitis in a rhesus monkey model [1]. |
In vitro | Grisnilimab setaritox (2.5 μg/mL; 24 h) exhibits cytotoxicity against T-lymphoblastic leukemia CEM cells [1]. |
In vivo | Grisnilimab setaritox (60 μg, 120 μg; intrathecal or intravenous injection; single dose) demonstrated potential in inhibiting T-ALL meningeal leukemia in a rhesus macaque model [1]. Additionally, grisnilimab setaritox (60 μg; intravenous injection; once weekly for six weeks, or daily for seven days) induced CSF granulocytosis and anti-immunotoxin antibodies in the same model [1]. |
Alias | WT1-RTA |
Cas No. | 2361013-29-6 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.